KR102488212B1 - Orostachys japonicas and Momordica charantia Linn complex-extract for improving blood sugar and method of manufacturing the same - Google Patents
Orostachys japonicas and Momordica charantia Linn complex-extract for improving blood sugar and method of manufacturing the same Download PDFInfo
- Publication number
- KR102488212B1 KR102488212B1 KR1020220014181A KR20220014181A KR102488212B1 KR 102488212 B1 KR102488212 B1 KR 102488212B1 KR 1020220014181 A KR1020220014181 A KR 1020220014181A KR 20220014181 A KR20220014181 A KR 20220014181A KR 102488212 B1 KR102488212 B1 KR 102488212B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- liver
- results
- confirmed
- complex
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 50
- 235000009811 Momordica charantia Nutrition 0.000 title claims abstract description 23
- 238000004519 manufacturing process Methods 0.000 title claims description 6
- 244000302512 Momordica charantia Species 0.000 title abstract description 20
- 239000008280 blood Substances 0.000 title abstract description 19
- 210000004369 blood Anatomy 0.000 title abstract description 19
- 241001165529 Orostachys japonica Species 0.000 title 1
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 22
- 235000008322 Trichosanthes cucumerina Nutrition 0.000 claims abstract description 20
- 239000002131 composite material Substances 0.000 claims abstract description 14
- 239000000203 mixture Substances 0.000 claims abstract description 5
- 241000699670 Mus sp. Species 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 239000012153 distilled water Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 244000078912 Trichosanthes cucumerina Species 0.000 claims 4
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 claims 2
- 235000013305 food Nutrition 0.000 claims 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims 1
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 claims 1
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 claims 1
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 claims 1
- LSHVYAFMTMFKBA-TZIWHRDSSA-N (-)-epicatechin-3-O-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-TZIWHRDSSA-N 0.000 claims 1
- LSHVYAFMTMFKBA-UHFFFAOYSA-N ECG Natural products C=1C=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-UHFFFAOYSA-N 0.000 claims 1
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 claims 1
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 claims 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 claims 1
- 235000005487 catechin Nutrition 0.000 claims 1
- 229950001002 cianidanol Drugs 0.000 claims 1
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 claims 1
- 235000012734 epicatechin Nutrition 0.000 claims 1
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 claims 1
- 229940030275 epigallocatechin gallate Drugs 0.000 claims 1
- 241000196324 Embryophyta Species 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 5
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 abstract description 2
- 230000003213 activating effect Effects 0.000 abstract description 2
- 239000004480 active ingredient Substances 0.000 abstract description 2
- 230000014509 gene expression Effects 0.000 description 33
- 210000004185 liver Anatomy 0.000 description 23
- 238000002474 experimental method Methods 0.000 description 18
- 238000000034 method Methods 0.000 description 13
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 11
- 239000008103 glucose Substances 0.000 description 11
- 238000005259 measurement Methods 0.000 description 11
- 230000008569 process Effects 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 230000003247 decreasing effect Effects 0.000 description 8
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 8
- 230000003178 anti-diabetic effect Effects 0.000 description 7
- 238000011888 autopsy Methods 0.000 description 7
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- 206010022489 Insulin Resistance Diseases 0.000 description 6
- 206010067125 Liver injury Diseases 0.000 description 6
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 6
- 241000018646 Pinus brutia Species 0.000 description 6
- 235000011613 Pinus brutia Nutrition 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 6
- 231100000234 hepatic damage Toxicity 0.000 description 6
- 229940125396 insulin Drugs 0.000 description 6
- 230000008818 liver damage Effects 0.000 description 6
- 210000000496 pancreas Anatomy 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 5
- 244000042664 Matricaria chamomilla Species 0.000 description 5
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 5
- 235000021314 Palmitic acid Nutrition 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000003472 antidiabetic agent Substances 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 238000010835 comparative analysis Methods 0.000 description 5
- 210000005228 liver tissue Anatomy 0.000 description 5
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 102100036264 Glucose-6-phosphatase catalytic subunit 1 Human genes 0.000 description 4
- 101710099339 Glucose-6-phosphatase catalytic subunit 1 Proteins 0.000 description 4
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 4
- 230000035508 accumulation Effects 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- 238000010195 expression analysis Methods 0.000 description 4
- 108091005995 glycated hemoglobin Proteins 0.000 description 4
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 3
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 3
- 229920002527 Glycogen Polymers 0.000 description 3
- 102000023984 PPAR alpha Human genes 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 229940096919 glycogen Drugs 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 230000037356 lipid metabolism Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000004445 quantitative analysis Methods 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000051325 Glucagon Human genes 0.000 description 2
- 108060003199 Glucagon Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 240000008670 Pinus densiflora Species 0.000 description 2
- 235000000405 Pinus densiflora Nutrition 0.000 description 2
- 244000184734 Pyrus japonica Species 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 2
- 229960004666 glucagon Drugs 0.000 description 2
- 108010070004 glucose receptor Proteins 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 210000001596 intra-abdominal fat Anatomy 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000007410 oral glucose tolerance test Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000011435 rock Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 210000004003 subcutaneous fat Anatomy 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 102100039164 Acetyl-CoA carboxylase 1 Human genes 0.000 description 1
- 102100021641 Acetyl-CoA carboxylase 2 Human genes 0.000 description 1
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 101000964894 Bos taurus 14-3-3 protein zeta/delta Proteins 0.000 description 1
- 241001164374 Calyx Species 0.000 description 1
- 241000220284 Crassulaceae Species 0.000 description 1
- 238000012270 DNA recombination Methods 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 101710188974 Fatty acid-binding protein, liver Proteins 0.000 description 1
- 102100026745 Fatty acid-binding protein, liver Human genes 0.000 description 1
- 101710189565 Fatty acid-binding protein, liver-type Proteins 0.000 description 1
- 206010073069 Hepatic cancer Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 101000963424 Homo sapiens Acetyl-CoA carboxylase 1 Proteins 0.000 description 1
- 101000677540 Homo sapiens Acetyl-CoA carboxylase 2 Proteins 0.000 description 1
- 101000824278 Homo sapiens Acyl-[acyl-carrier-protein] hydrolase Proteins 0.000 description 1
- 101100041816 Homo sapiens SCD gene Proteins 0.000 description 1
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 241000519695 Ilex integra Species 0.000 description 1
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 1
- 102100022119 Lipoprotein lipase Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 241000304370 Orostachys Species 0.000 description 1
- 108090000472 Phosphoenolpyruvate carboxykinase (ATP) Proteins 0.000 description 1
- 102100034792 Phosphoenolpyruvate carboxykinase [GTP], mitochondrial Human genes 0.000 description 1
- 238000012356 Product development Methods 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 101150097713 SCD1 gene Proteins 0.000 description 1
- 108091006299 SLC2A2 Proteins 0.000 description 1
- 108091006300 SLC2A4 Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102100023537 Solute carrier family 2, facilitated glucose transporter member 2 Human genes 0.000 description 1
- 102100033939 Solute carrier family 2, facilitated glucose transporter member 4 Human genes 0.000 description 1
- 102100028897 Stearoyl-CoA desaturase Human genes 0.000 description 1
- 108010074436 Sterol Regulatory Element Binding Protein 1 Proteins 0.000 description 1
- 108010074438 Sterol Regulatory Element Binding Protein 2 Proteins 0.000 description 1
- 102100026839 Sterol regulatory element-binding protein 1 Human genes 0.000 description 1
- 102100026841 Sterol regulatory element-binding protein 2 Human genes 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 244000195452 Wasabia japonica Species 0.000 description 1
- 235000000760 Wasabia japonica Nutrition 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000011759 adipose tissue development Effects 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 230000006372 lipid accumulation Effects 0.000 description 1
- 230000004132 lipogenesis Effects 0.000 description 1
- 102000004311 liver X receptors Human genes 0.000 description 1
- 108090000865 liver X receptors Proteins 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 108091008023 transcriptional regulators Proteins 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/41—Crassulaceae (Stonecrop family)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 와송 및 여주 복합 추출물을 유효성분으로 포함하는 당뇨병 예방, 개선 또는 치료용 조성물에 관한 것이다.
본 발명은 이에 따라 식물을 이용하여 부작용이 없고, 혈당 수치를 정상범위로 낮추면서 췌장베타세포를 활성시킴으로써 효율적으로 당뇨병을 개선 또는 치료할 수 있다.The present invention relates to a composition for preventing, improving or treating diabetes comprising a composite extract of Waspong and Bitter gourd as an active ingredient.
Accordingly, the present invention can effectively improve or treat diabetes by activating pancreatic beta cells while lowering the blood sugar level to a normal range without side effects using plants.
Description
본 발명은 혈당을 개선할 수 있는 와송·여주 복합추출물 및 이의 제조방법에 관한 것으로 보다 상세하게는 와송과 여주를 이용하여 혈당을 개선하여 효율적으로 당뇨를 개선, 예방 및 치료할 수 있는 와송·여주 복합추출물 및 이의 제조방법에 관한 것이다.The present invention relates to a composite extract of Waspong and bitter gourd that can improve blood sugar and a method for manufacturing the same, and more particularly, to improve blood sugar using Wasp and bitter gourd bitter gourd, effectively improving, preventing and treating diabetes. It relates to an extract and a method for preparing the same.
본 발명은 과제 결과물로서 과제정보는 다음과 같다. The present invention is a task result, and the task information is as follows.
1. 과제번호 : 2017-나-61. Task number: 2017-B-6
2. 부처명 : 전라북도2. Department Name: Jeollabuk-do
3. 연구관리 전문기관 : 전북테크노파크 3. Organization specializing in research management: Jeonbuk Techno Park
4. 연구사업명 : 2017년도 전라북도 선도기업 기술개발 역량강화지원사업4. Research Project Name: 2017 Jeollabuk-do Leading Enterprise Technology Development Capacity Building Support Project
5. 연구과제명 : 와송을 활용한 당뇨병 개선 바이오 소재 및 제품개발 5. Title of research project: Diabetes improvement bio material and product development using Wasong
6. 주관기관 : 제너럴바이오(주)6. Supervisor: General Bio Co., Ltd.
7. 연구기간 : 2017.10.01 ~ 2018.09.307. Research period: 2017.10.01 ~ 2018.09.30
당뇨병은 탄수화물 대사에 작용하는 인슐린 (insulin)의 작용이 정상적으로 이루어지지 않아 일어나는 내분비 장애의 가장 대표적인 질병으로, 주로 소아에서 발생하며 췌장 (pancreas)의 인슐린 분비가 감소에 의한 제1형 당뇨병 및 성인에서 주로 발생하며 인체 각 조직이 인슐린에 대해 무반응성의 인슐린 저항성 증상을 나타내는 제2형 당뇨병으로 분류된다.Diabetes mellitus is the most representative endocrine disorder that occurs when the action of insulin, which acts on carbohydrate metabolism, is not normally performed. It mainly occurs and is classified as
당뇨병의 주된 치료제로서는 설포닐우레아 (sulfonylureas)계 약물, 비구아니드 (biguanides)계 등의 경구로 섭취하는 혈당강하제와 DNA 재조합법에 의하여 얻은 인슐린 등이 사용되고 있다. 하지만 이런 약물들은 저혈당증 유발, 신장독성, 유산증, 설사와 배탈, 면역거부반응 등 많은 부작용을 가지고있어 부작용이 적은 천연물을 이용하려는 연구가 활발해지고 있다.As the main treatment for diabetes, orally ingested hypoglycemic agents such as sulfonylureas drugs and biguanides and insulin obtained by DNA recombination are used. However, these drugs have many side effects such as induction of hypoglycemia, renal toxicity, lactic acidosis, diarrhea and stomach upset, and immune rejection, so studies to use natural products with fewer side effects are becoming more active.
한편, 와송(瓦松)은 바위솔(Orostachys japonicus A. Berger)이라 하며 일명 암송(岩松), 옥송(屋松), 작엽하초(昨葉何草) 등으로 불리는 돌나물과(Crassulaceae)의 다년생 초본 식물로서 한방에서 해열, 소종, 지혈, 이습 등에 사용되며[金在佶, 1984, 原色天然藥物大事典(上卷), 南山堂, 서울, p.447] 민간요법으로 암치료에도 많이 이용되고 있다[배성식,1990, 한방과 건강, 1, 26].On the other hand, pine (瓦松) is called rock brush (Orostachys japonicus A. Berger) and is a perennial herbaceous plant of the Crassulaceae, also known as pine (岩松), jade pine (屋松), hacho (昨葉何草), etc. It is used in oriental medicine for fever, small boils, hemostasis, and dampness [Kim Jae-soo, 1984, Original Color Celestial Plants Daesajang (上卷), Namsan-dang, Seoul, p.447], and is also widely used for cancer treatment as a folk remedy [ Seongsik Bae, 1990, Herbal Medicine and Health, 1, 26].
이 식물은 바위 곁에 붙어서 자라는 육질의 다년생 초본이지만 꽃이 피고 열매를 맺으면 고사하는 특징이 있다. 근생엽은 로제트형으로 퍼지며 끝이 굳어져서 가시처럼 되고 원줄기에 잎이 달리며 엽병이 없고 여름철에 나오는 근생엽과 더불어 끝이 굳어지지 않고 다만 뾰족해질 뿐이며 피침형으로서 녹색이지만 자주색 또는 분을 칠한 듯한 백색인것도 있다. 꽃은 9월에 피고 백색이며 총상화서는 길이 6∼15cm로서 화병이 없는 꽃이 밀착하고 포는 피침형이며 끝이 뾰족하다. 꽃받침은 5개로서 피침형이고 녹색이며 꽃잎도 5개로서 피침형 예두이고 길이 6mm 정도이다. 수술은10개이며 꽃잎보다 길고 자방은 5개이며 화분은 적색이지만 점차 흑색으로 된다[이창복, 1979, 大韓植物圖鑑, 鄕文社 서울, p.402]. 와송은 여름부터 가을에 걸쳐 채취하며 뿌리를 제거한 전초(全草)를 햇볕에 말려 약용으로 한다[金在佶, 1984, 原色天然藥物大事典(上卷), 南山堂, 서울, p.447].This plant is a fleshy perennial herb that grows attached to rocks, but it is characterized by withering away when it blooms and bears fruit. Radical leaves spread in a rosette shape, the ends harden and become like thorns, the leaves hang on the main stem, there is no petiole, and the ends do not harden together with the rhizome leaves that appear in summer, but only become sharp, lanceolate, green, but purple or powdered white. there is. Flowers bloom in September, white, racemes are 6-15cm long, flowers without vases are closely attached, bracts are lanceolate, and the ends are sharp. There are 5 calyxes, lanceolate, green, and 5 petals, lanceolate acute, about 6mm long. It has 10 stamens, longer than petals, and 5 ovaries. The pollen is red, but gradually turns black [Lee Chang-bok, 1979, Daehan Plant Research, Hyangmunsa Seoul, p.402]. Wasong is collected from summer to autumn, and the outposts with the roots removed are dried in the sun for medicinal purposes [Kim Jae-woo, 1984, Original Color Celestial Plants Daesagi (上卷), Namsanjang, Seoul, p.447] .
와송을 본초학적으로 문헌을 통하여 고찰하여 보면 당본초(唐本草)에는 구중(口中)의 건조(乾燥)와 통증에 사용한다고 하며 본초강목에는 대장하혈에 물로 추출하여 복용하고, 모든 상처에 도포하면 수렴 효과가 있다고 하며 본초재신에는 백독(百毒)을 치료하고 종(腫)을 소실시키며 분류초약성에는 치질의 종통출혈을 다스리는 데는 약초를 전액(煎液)으로하여 세척한다고 하며 본초재신에는 창(瘡)과 유(癒)에 효과가 있다고 한다[上海科學技術出版社 小學館編 ;中藥大事典, 小學館, 1985, p.526].If you look at wasa pine through herbal literature, it is said that it is used for dryness and pain in the mouth in dangboncho (唐本草). It is said to have an astringent effect, and in herbal remedies, it treats white poison and eliminates tumors, and in classification herbal medicine, it is said that all herbs are used to wash hemorrhoids to control hemorrhoidal pain and bleeding. It is said to be effective for (瘡) and Yu (癒) [上海科學技術出版社 小學館編 ;中藥大事典, 小學館, 1985, p.526].
한편, 대한민국 공개특허공보 제10-2005-0006964호(이하 ‘특허문헌 1’이라 한다)에 게재된 발명에는 와송을 이용한 항당뇨성 조성물이 개시되어 있다.On the other hand, in the invention published in Republic of Korea Patent Publication No. 10-2005-0006964 (hereinafter referred to as 'Patent Document 1'), an antidiabetic composition using Wasong is disclosed.
그러나 특허문헌 1은 와송만을 이용하여 당뇨병 개선 또는 치료에 효능이 제한적인 문제가 있다.However,
본 발명은 와송만을 이용할 경우에 효능이 제한적인 것을 해결하기 위하여 안출된 것으로, 본 발명에서 해결하고자 하는 과제는 와송 이외에 다른 식물, 즉 여주를 더 부가하여 효율적으로 당뇨를 개선, 예방 및 치료할 수 있는 추출물 및 이의 제조방법을 제공하는 것이다.The present invention has been devised to solve the limited efficacy when using only Waspsong, and the problem to be solved in the present invention is to improve, prevent and treat diabetes efficiently by adding other plants, that is, bitter gourd, in addition to Waspsong. It is to provide an extract and a manufacturing method thereof.
위와 같은 과제를 해결하기 위한 본 발명에 따른 추출물은 와송 및 여주 복합 추출물을 유효성분으로 포함하는 것을 기술적 특징으로 한다.The extract according to the present invention for solving the above problems is technically characterized by containing a composite extract of Waspong and Goji bitter gourd as an active ingredient.
위와 같은 과제를 해결하기 위한 본 발명에 따른 추출물의 제조방법은 와송 분말을 증류수에 녹인 다음 환류 추출하는 단계; 여주 분말을 증류수에 녹인 다음 환류 추출하는 단계; 및 상기 와송 추출물과 상기 여주 추출물을 중량비 기준으로 8:2의 비율로 혼합하는 단계를 포함하여 구성되는 것을 기술적 특징으로 한다.Method for producing an extract according to the present invention for solving the above problems is dissolved in distilled water wasong powder and then reflux extraction; Dissolving bitter gourd powder in distilled water and then extracting under reflux; and mixing the waspsong extract and the bitter gourd extract in a weight ratio of 8:2.
본 발명에 따른 추출물은 식물을 이용하여 부작용이 없고, 혈당 수치를 정상범위로 낮춤과 동시에 췌장베타세포를 활성시킴으로써 효율적으로 당뇨병을 개선 또는 치료할 수 있다.The extract according to the present invention has no side effects by using plants, and can efficiently improve or treat diabetes by lowering blood sugar levels to a normal range and activating pancreatic beta cells at the same time.
도 1 및 도 2는 혈당측정 결과를 나타내는 그래프
도 3은 당화혈색소의 측정 결과를 나타내는 그래프
도 4 및 도 5는 경구 당 부하검사 결과를 나타내는 그래프
도 6 및 도 7은 췌장 H&E 염색 결과를 나타내는 사진 및 그래프
도 8은 췌장의 면역염색 결과를 나타내는 사진
도 9는 피하 및 복강 내 지방조직 부검 결과 사진
도 10은 간의 지방조직 부검 결과 사진
도 11은 부검 후 체중 측정 결과를 나타내는 그래프
도 12는 부검 후 간 무게 측정 결과를 나타내는 그래프
도 13은 간 무게/체중 비율 결과를 나타내는 그래프
도 14 및 도 15는 간 손상 수치 측정 결과를 나타내는 그래프
도 16 및 도 17은 지방축적 측정 결과를 나타내는 그래프
도 18은 간의 H&E 염색 결과를 나타내는 사진
도 19 및 도 20은 간의 Oil-red O 염색 결과를 나타내는 사진 및 그래프
도 21은 지질대사 관련 유전자의 발현 결과를 나타내는 그래프
도 22는 지질생합성 관련 유전자의 발현 결과를 나타내는 그래프
도 23은 지질대사 및 지질생합성 관련 전사조절인자의 발현 결과를 타나내는 그래프
도 24는 웨스턴블랏을 통한 Akt 발현 결과를 나타내는 사진
도 25는 당 수용체 및 당 신생합성 관련 유전자의 발현 결과를 나타내는 그래프
도 26은 와송 추출물이 투여된 인슐린 저항성 실험모델의 유전자 발현 분석 결과를 나타낸 그래프
도 27은 와송·여주 복합추출물이 투여된 인슐린 저항성 실험모델의 유전자 발현 분석 결과를 나타낸 그래프1 and 2 are graphs showing blood glucose measurement results
3 is a graph showing the measurement results of glycated hemoglobin
4 and 5 are graphs showing oral glucose tolerance test results
6 and 7 are photographs and graphs showing pancreatic H&E staining results
8 is a photograph showing the results of immunostaining of the pancreas
Figure 9 is a picture of the autopsy results of subcutaneous and intra-abdominal adipose tissue
10 is a photograph of the liver adipose tissue autopsy result
11 is a graph showing the results of weight measurement after autopsy
12 is a graph showing liver weight measurement results after autopsy
13 is a graph showing liver weight / body weight ratio results
14 and 15 are graphs showing liver damage measurement results
16 and 17 are graphs showing fat accumulation measurement results
18 is a photograph showing the results of H&E staining of the liver
19 and 20 are photographs and graphs showing results of Oil-red O staining of liver
21 is a graph showing the expression results of lipid metabolism related genes
22 is a graph showing the expression results of lipid biosynthesis-related genes
23 is a graph showing the expression results of transcriptional regulators related to lipid metabolism and lipid biosynthesis
24 is a photograph showing Akt expression results through western blotting
25 is a graph showing the expression results of genes related to sugar receptors and glycogen synthesis
Figure 26 is a graph showing the results of gene expression analysis of the insulin resistance experimental model to which Wassong extract was administered
Figure 27 is a graph showing the results of gene expression analysis of the insulin resistance experimental model administered with Wassong · Bitter gourd complex extract
본 명세서 및 청구범위에 사용된 용어나 단어는 "발명자는 그 자신의 발명을 가장 최선의 방법으로 설명하기 위해 용어의 개념을 적절하게 정의할 수 있다는 원칙"에 입각하여 본 발명의 기술적 사상에 부합하는 의미와 개념으로 해석되어야지, 통상적이거나 사전적인 의미로 한정해서 해석되서는 안 된다.The terms or words used in this specification and claims conform to the technical spirit of the present invention based on the "principle that the inventor can appropriately define the concept of terms in order to explain his or her invention in the best way" It should be interpreted as the meaning and concept of
따라서 본 명세서에 기재된 실시예와 도면에 도시된 구성은 본 발명의 가장 바람직한 실시예에 불과할 뿐이고, 본 발명의 기술적 사상을 모두 대변하는 것은 아니므로, 본 출원시점에 있어서 이들을 대체할 수 있는 다양한 균등물과 변형 예들이 있을 수 있음을 이해해야 한다.Therefore, the embodiments described in this specification and the configurations shown in the drawings are only the most preferred embodiments of the present invention, and do not represent all of the technical spirit of the present invention, so various equivalents that can replace them at the time of the present application It should be understood that there may be water and variations.
실시예. 와송·여주 복합추출물Example. Wasong·Yeoju Complex Extract
와송 및 여주의 열매는 남원에 소재한 영농조합법인으로부터 구매하였다. 와송 및 여주의 지상부로 이루어진 건조분말 1kg을 증류수 10L에 넣고 균질기(homogenizer)를 이용해 밤새 저으면서 2회에 걸쳐 환류추출하였다. 추출물은 동결건조시켜 와송·여주 복합 추출물을 완성하였다. 본 발명에서 사용되는 와송과 여주의 혼합 비율은 8:2의 비율로 혼합하였다. 와송·여주 복합추출물의 조성을 HPLC(High-performance liquid chromatography) 분석한 결과 5개의 주요 성분이 확인되었고, 그 결과는 아래의 표 1과 같다.Fruits of Wasong and Yeoju were purchased from a farming association located in Namwon. 1 kg of dry powder consisting of the aerial parts of Japanese pine and bitter gourd was added to 10 L of distilled water and extracted twice under reflux while stirring overnight using a homogenizer. The extract was freeze-dried to complete Wasong·Yeoju composite extract. The mixing ratio of waspsong and bitter gourd used in the present invention was mixed at a ratio of 8:2. As a result of HPLC (High-performance liquid chromatography) analysis of the composition of the Wasson·Yeoju composite extract, five main components were identified, and the results are shown in Table 1 below.
실험예 1. 항당뇨 지표에 대한 영향 평가Experimental Example 1. Evaluation of effects on anti-diabetic indicators
1-1. 실험 준비1-1. Experiment preparation
실험을 위해 5주령의 수컷 db/db 마우스와 같은 연령의 wild type C57BL/Ksj-db/+(db/+) 마우스를 준비하였다. 환경은 일반적인 환경 조건(24±2℃, 50±5%의 습도)을 유지하였고, 식이는 멸균된 표준식단으로 공급하였으며, 물은 자유롭게 섭취하도록 공급하였다. 이하에서 수행된 실험은 모두 전북대 동물보호윤리위원회(CNNU 2018-038)의 지침에 맞게 수행하였다. 2주간의 순화과정이 지난 다음 db/+ (그룹 당 6마리) 또는 db/db (그룹당 8마리) 마우스를 무작위적으로 4개의 그룹으로 나누었고, 와송·여주 복합추출물을 다음과 같은 농도로 투여하였다;0, 100, 200 및 400 mg/kg/day. 와송·여주 복합추출물은 식염수에 녹여서 경구섭취시켰고, 섭취 주기는 1주일 중 5일, 하루에 한 번 투여하였고 실험은 6주간 수행하였다.For the experiment, 5-week-old male db/db mice and wild-type C57BL/Ksj-db/+ (db/+) mice of the same age were prepared. The environment maintained general environmental conditions (24 ± 2 ℃, humidity of 50 ± 5%), the diet was supplied as a sterilized standard diet, and water was provided to be freely consumed. The experiments performed below were all conducted according to the guidelines of the Animal Care Ethics Committee of Chonbuk National University (CNNU 2018-038). After a 2-week acclimatization process, db/+ (6 mice per group) or db/db (8 mice per group) mice were randomly divided into 4 groups, and the Waspsong·Mochi chamomile complex extract was administered at the following concentrations. ;0, 100, 200 and 400 mg/kg/day. Wasong·Yeoju extract was dissolved in saline and taken orally. The intake cycle was 5 days a week, once a day, and the experiment was conducted for 6 weeks.
1-2. 실험 과정1-2. experimental process
1-1의 마우스를 최소 8시간동안 절식한 후 (1)혈중 포도당 수치와 (2)당화혈색소 수치를 측정하였고, 그 뒤 (3)당(2g/kg 체중)을 경구 투여하고 혈중 포도당 수치를 0, 30, 60, 90, 120분 후 각각 측정하여 혈당 조절 능력을 평가하였다. After the mice in 1-1 were fasted for at least 8 hours, (1) blood glucose levels and (2) glycated hemoglobin levels were measured, and then (3) sugar (2 g/kg body weight) was orally administered and blood glucose levels were measured. After 0, 30, 60, 90, and 120 minutes, respectively, blood glucose control ability was evaluated.
1-3. 실험 결과1-3. Experiment result
(1)절식 후 혈당측정결과(1) Blood glucose measurement result after fasting
도 1에 도시된 바와 같이 와송·여주 복합추출물을 투여 받은 당뇨 유발 마우스 그룹에서 혈당이 유의적으로 감소하는 결과를 확인하였다.As shown in FIG. 1, it was confirmed that the blood glucose level was significantly reduced in the diabetic mouse group administered with the Wassong·Mongolian complex extract.
이 결과를 바탕으로 초기 혈당수치와의 차이를 비교분석한 결과 도 2에 도시된 바와 같이 혈당의 변화량 역시 와송·여주 복합추출물투여에 의하여 감소한 것을 확인하였다.Based on this result, as a result of comparative analysis of the difference from the initial blood glucose level, it was confirmed that the change in blood sugar was also reduced by the administration of the extract of Wassong · Goji bitter gourd complex, as shown in FIG.
(2)당화혈색소(HbA1c) 측정결과(2) Glycated hemoglobin (HbA1c) measurement result
도 3에 도시된 바와 같이 와송·여주 복합추출물 투여 받은 당뇨 유발 마우스 그룹에서 당화혈색소의 측정값이 유의적으로 감소하는 것을 확인하였다.As shown in FIG. 3, it was confirmed that the measured value of glycated hemoglobin was significantly decreased in the diabetic mouse group administered with the Wassong·moji chamomile complex extract.
(3)경구 당 부하검사결과(oral glucose tolerance test)(3) Results of oral glucose tolerance test
도 4 및 도 5에 도시된 바와 같이 db/db 마우스 그룹에서 혈당은 120분 후에도 초기 혈당에 비하여 현저히 증가된 것을 확인하였다. 반면 와송·여주 복합추출물을 투여 받은 그룹에서는 당 투여 후 시간이 지남에 따라 혈당이 감소하는 유의적으로 감소하는 결과를 확인하였다. 이러한 결과를 와송·여주 복합추출물투여에 의하여 당뇨 유발 마우스에서 혈당 조절 능력이 개선됨을 나타낸다.As shown in FIGS. 4 and 5 , it was confirmed that the blood glucose level in the db/db mouse group significantly increased after 120 minutes compared to the initial blood glucose level. On the other hand, in the group that received the Wasong·Yeoju complex extract, it was confirmed that blood sugar decreased significantly over time after sugar administration. These results indicate that the blood glucose control ability is improved in diabetic mice by the administration of the Wassong·moji chamomile complex extract.
실험예 2. 췌장의 조직병리학적 변화 분석Experimental Example 2. Analysis of histopathological changes in the pancreas
2-1. 실험 준비2-1. Experiment preparation
췌장 조직을 준비하였다.Pancreatic tissue was prepared.
2-2. 실험 과정2-2. experimental process
포르말린 고정 후 일반적인 처리과정을 거친 조직절편을 H&E 염색을 통하여 당뇨유발에 의한 췌장의 병리학적 변화를 관찰하였다.Pathological changes in the pancreas caused by diabetes were observed through H&E staining of the tissue sections that had undergone normal processing after fixation in formalin.
포르말린 고정 조직을 일반적인 조직 처리과정 후 조직절편을 면역 염색(Immunohistochemistry, IHC)을 통하여 당뇨유발에 의한 췌장의 병리학적 변화를 관찰하였다.After normal tissue processing of formalin-fixed tissue, tissue sections were examined for pathological changes in the pancreas caused by diabetes through immunohistochemistry (IHC).
2-3. 실험 결과2-3. Experiment result
췌장 H&E 염색 결과, 도 6 및 도 7에 도시된 바와 같이 인슐린 저항성으로 인한 췌장의 랑게르한스 섬 면적이 현저히 증가한 것이 db/db 마우스 군에서 관찰되었는데, 이러한 변화는 와송·여주 복합추출물투여에 의하여 유의적으로 감소하는 것을 확인하였다.As a result of pancreatic H&E staining, as shown in Figs. 6 and 7, a significant increase in the area of islets of Langerhans in the pancreas due to insulin resistance was observed in the db / db mouse group. was confirmed to decrease.
면역염색을 통하여 인슐린 및 글루카곤의 발현 양상을 비교분석해본 결과, 도 8에 도시된 바와 같이 db/db 마우스 군에서 와송·여주 복합추출물 처리함으로써 인슐린 양성 세포가 증가하였고, 글루카곤 분비양상이 정상에 유사해지는 결과를 확인하였다.As a result of comparative analysis of the expression patterns of insulin and glucagon through immunostaining, as shown in FIG. 8, insulin-positive cells were increased by treating the db / db mouse group with the composite extract of Japanese bitter melon and bitter gourd, and the secretion of glucagon was similar to normal. The cancellation result was confirmed.
실험예 2의 결과를 통해 와송·여주 복합추출물이 2형 당뇨병이 발생한 개체의 췌장에 긍정적인 영향을 미치는 것을 알 수 있다.Through the results of Experimental Example 2, it can be seen that the Wassong·Mongolia complex extract has a positive effect on the pancreas of individuals with
실험예 3. 부검 육안소견 및 간 무게, 체중 비교Experimental Example 3. Comparison of autopsy visual findings, liver weight, and body weight
3-1. 실험 준비3-1. Experiment preparation
1-1과 같이 마우스를 준비하였다.Mice were prepared as in 1-1.
3-2. 실험 과정3-2. experimental process
실험 기간 6주 후 부검을 실시하였다. 부검 전 8시간 동안은 금식시켰다.An autopsy was performed after 6 weeks of the experimental period. They were fasted for 8 hours before necropsy.
3-3. 실험 결과3-3. Experiment result
(1) 부검 육안소견 결과(1) Result of autopsy macroscopic findings
도 9에 도시된 바와 같이 당뇨가 유발된 db/db 마우스 그룹은 db/+ 그룹에 비하여 피하 및 복강 내 지방조직의 크기가 증가된 것을 확인하였다. 반면, 와송·여주 복합추출물 투여에 의한 지방조직의 변화를 확인할 수 없었다.As shown in FIG. 9 , it was confirmed that the diabetic db/db mouse group had increased subcutaneous and intra-abdominal adipose tissue sizes compared to the db/+ group. On the other hand, it was not possible to confirm the change of adipose tissue by administration of Wasong·Yeoju complex extract.
(2)간 무게 및 체중 측정 결과(2) Liver weight and weight measurement results
간 크기의 변화는 도 10에 도시된 바와 같다. 도 11 내지 13에 도시된 바와 같이 당뇨가 유발된 db/db 마우스 그룹에서 db/+ 그룹에 비하여 체중 및 간의 무게가 증가한 결과를 확인하였다. 반면 와송·여주 복합추출물투여에 의하여 체중 및 간 무게 혹은 그 비율이 미약하게 감소하는 것을 확인하였으나, 통계적 유의성은 확인할 수 없었다.Changes in liver size are as shown in FIG. 10 . As shown in FIGS. 11 to 13, it was confirmed that the body weight and liver weight increased in the diabetic db/db mouse group compared to the db/+ group. On the other hand, it was confirmed that the body weight and liver weight or the ratio thereof decreased slightly by the administration of the mixed extract of Wasong·Yeoju. However, statistical significance could not be confirmed.
실험예 4. 당뇨병에 의한 간 손상 및 지방침착 확인Experimental Example 4. Confirmation of liver damage and fat deposition caused by diabetes
4-1. 실험 준비4-1. Experiment preparation
1-1.과 같은 방법으로 마우스를 준비하였다.Mice were prepared in the same way as in 1-1.
4-2. 실험 과정4-2. experimental process
4-1의 마우스에서 채취한 혈액시료를 원심분리하여 혈청을 얻고, (1)간 손상 관련 효소인 ALT(alanine aminotransferase), AST(aspartate transaminase)를 측정하였고, (2)9-1 마우스에서 채취한 간에서 중성지방(triglyceride, 이하 ‘TG’) 및 총 콜레스테롤의 양(total cholesterol, 이하 ‘TC’)을 측정하였다.Blood samples collected from mice in 4-1 were centrifuged to obtain serum, (1) ALT (alanine aminotransferase) and AST (aspartate transaminase), which are enzymes related to liver damage, were measured, (2) collected from 9-1 mice Triglyceride (hereinafter referred to as 'TG') and total cholesterol (hereinafter referred to as 'TC') were measured in one liver.
4-3. 실험 결과4-3. Experiment result
(1)간 손상 수치 측정 결과(1) Measurement results of liver damage
혈청학적 분석을 통하여 도 14 및 도 15에 도시된 바와 같이 와송·여주 복합추출물 투여에 의해 ALT 및 AST의 수치가 유의적으로 감소한 것을 확인하였다.As shown in FIGS. 14 and 15 through serological analysis, it was confirmed that the levels of ALT and AST were significantly decreased by the administration of the composite extract of Wassong·Mongolia.
(2)TG 및 TC 측정 결과(2) TG and TC measurement results
도 16 및 도 17에 도시된 바와 같이 와송·여주 복합추출물투여에 의하여 지방축적이 유의적으로 감소한 것을 확인하였다.As shown in FIGS. 16 and 17, it was confirmed that the fat accumulation was significantly reduced by the administration of the Wassong·moji chamomile complex extract.
실험예 5. 간의 조직병리학적 변화 분석1Experimental Example 5. Analysis of histopathological changes in the
5-1. 실험 준비5-1. Experiment preparation
간 조직을 준비하였다.Liver tissue was prepared.
5-2. 실험 과정5-2. experimental process
포르말린 고정 후 일반적인 처리과정을 거친 조직절편을 H&E 염색을 통하여 당뇨유발에 의한 간의 병리학적 변화를 관찰하였다.After formalin fixation, pathological changes in the liver due to diabetes induction were observed through H&E staining of tissue sections that had undergone general processing.
5-3. 실험 결과5-3. Experiment result
간의 H&E 염색 결과, 도 18에 도시된 바와 같이 db/db 마우스 군에서 간세포 변성(hepatocellular hypertrophy, ballooning degeneration) 및 지방침착(stratosis)을 관찰할 수 있었으며, 이러한 양상은 와송·여주 복합추출물투여에 의해 유의적으로 감소되는 것을 확인하였다.As a result of H&E staining of the liver, as shown in FIG. 18, hepatocellular hypertrophy and ballooning degeneration and fat deposition (stratosis) were observed in the db/db mouse group, and these aspects were observed by A significant decrease was confirmed.
실험예 3 내지 5의 결과를 종합하면, 여주·와송·여주 복합추출물이 당뇨에 의해 발생한 간 손상을 감소시키고, 간 손상과 관련된 지방증과 혈당을 조절함으로써 항당뇨 효과가 있음을 알 수 있다.Summarizing the results of Experimental Examples 3 to 5, it can be seen that the bitter gourd · Wassong · bitter gourd complex extract has an antidiabetic effect by reducing liver damage caused by diabetes and controlling steatosis and blood sugar related to liver damage.
실험예 6. 간의 조직병리학적 변화 분석2Experimental Example 6. Analysis of histopathological changes in the
6-1. 실험 준비6-1. Experiment preparation
간 조직을 준비하였다.Liver tissue was prepared.
6-2. 실험 과정6-2. experimental process
동결고정조직의 절편을 Oil-red O 염색을 통하여 당뇨유발에 의한 간의 지방침착을 조직수준에서 관찰하였다.Fat deposition in the liver caused by diabetes was observed at the tissue level through Oil-red O staining of frozen tissue sections.
6-3. 실험 결과6-3. Experiment result
간의 Oil-red O 염색 결과, 도 19 및 도 20에 도시된 바와 같이 H&E 염색조직 관찰 결과와 유사하게 지방침착이 와송·여주 복합추출물투여에 의하여 현저히 감소하는 것을 확인하였다.As a result of Oil-red O staining of the liver, as shown in FIGS. 19 and 20, it was confirmed that fat deposition was significantly reduced by the administration of the combined extract of Waspong and Bitter gourd, similar to the results of observation of H&E stained tissue.
실험예 7. 지방 관련 유전자 발현 분석Experimental Example 7. Fat-related gene expression analysis
7-1. 실험 과정7-1. experimental process
간 조직에서 mRNA를 추출하여 cDNA를 합성하였다. 다양한 유전자의 발현 변화를 qRT-PCR을 통해 상대정량분석을 실시하여 와송·여주 복합추출물 의한 유전자 발현양상의 변화를 비교분석하였다.cDNA was synthesized by extracting mRNA from liver tissue. Relative quantitative analysis was performed on the expression changes of various genes through qRT-PCR to compare and analyze the changes in gene expression patterns caused by the composite extracts of Wassong·Mongolia.
7-2. 실험 결과7-2. Experiment result
지질대사 관련 인자인 Apo B, LPL, 및 L-FABP의 발현을 비교분석한 결과, 도 21에 도시된 바와 같이 와송·여주 복합추출물투여에 의하여 당뇨 유발 마우스의 간장에서 유의적으로 감소하는 결과를 확인하였다.As a result of comparative analysis of the expression of Apo B, LPL, and L-FABP, which are lipid metabolism-related factors, as shown in FIG. Confirmed.
지질생합성(de novo lipogenesis)관련 인자인 ACCα, ACCβ, FAS, 및 SCD1의 발현을 비교분석한 결과, 도 22에 도시된 바와 같이 와송·여주 복합추출물투여에 의하여 당뇨 유발 마우스의 간장에서 유의적으로 감소하는 결과를 확인하였다.As a result of comparative analysis of the expression of ACCα, ACCβ, FAS, and SCD1, which are lipid biosynthesis (de novo lipogenesis) related factors, as shown in FIG. Decreasing results were confirmed.
그리고 위와 같은 변화와 밀접한 연관이 있는 전자조절인자 및 그 관련 인자인 SREBP-1, SREBP-2 및 LXRα의 발현을 비교분석한 결과, 도 23에 도시된 바와 같이 와송·여주 복합추출물투여에 의하여 당뇨 유발 마우스의 간장에서 유의적으로 감소하는 결과를 확인하였다. 반면, 간 보호 및 항 당뇨효능이 있다고 알려져 있는 PPARα의 발현은 유의적으로 증가하는 결과를 확인하였다.In addition, as a result of comparative analysis of the expression of electronic regulators closely related to the above changes and their related factors, SREBP-1, SREBP-2 and LXRα, as shown in FIG. A significant decrease in the liver of induced mice was confirmed. On the other hand, it was confirmed that the expression of PPARα, which is known to have hepatoprotective and anti-diabetic effects, significantly increased.
실험예 6 및 실험예 7의 결과를 종합하면, 와송·여주 복합추출물이 2형 당뇨병이 발생한 개체의 간 지방 대사에 관여하여 간에서의 지방축적, 즉 지방증(hepatic steatosis)을 방지하는데 효과가 있음을 알 수 있다.Summarizing the results of Experimental Example 6 and Experimental Example 7, the Wassong·moji chamomile complex extract is involved in liver fat metabolism of individuals with
실험예 8. 당 대사 관련 유전자 발현 분석Experimental Example 8. Gene expression analysis related to sugar metabolism
8-1. 실험 과정8-1. experimental process
간 조직에서 단백질을 추출하여 웨스턴 블랏 분석(Western blot analysis)을 통한 단백질 발현 분석 및 간 조직에서 mRNA를 추출하여 cDNA를 합성하였다.Protein was extracted from liver tissue, protein expression was analyzed through Western blot analysis, and cDNA was synthesized by extracting mRNA from liver tissue.
다양한 유전자의 발현 변화를 qRT-PCR을 통하여 상대정량분석을 실시하여 와송·여주 복합추출물에 의한 유전자 발현양상의 변화를 비교분석하였다.Relative quantitative analysis was performed on the expression changes of various genes through qRT-PCR to compare and analyze the changes in gene expression patterns by the composite extracts of Wassong·Moorbita japonica.
8-2. 실험 결과8-2. Experiment result
도 24에 도시된 바와 같이 인슐린 신호전달 및 당 수용체 발현조절에 중요한 역할을 하는 Akt의 활성화(인산화)가 와송·여주 복합추출물을 투여한 마우스의 간에서 증가하는 것을 확인하였다.As shown in FIG. 24, it was confirmed that the activation (phosphorylation) of Akt, which plays an important role in insulin signaling and regulation of glucose receptor expression, was increased in the livers of mice administered with the pine-moistennium composite extract.
당 수용체(GLUT2, 4)의 발현을 확인해 본 결과, 당 수용체 발현이 와송·여주 복합추출물 처리에 의하여 유의적으로 증가하는 결과를 확인하였다(도 25 참조).As a result of confirming the expression of sugar receptors (GLUT2, 4), it was confirmed that the expression of the sugar receptor was significantly increased by the treatment with the composite extract of Japanese pine and bitter melon (see FIG. 25).
당 신생합성 관련 유전자(G6Pase, PEPCK)의 발현을 확인해 본 결과, 와송·여주 복합추출물 처리에 의하여 당뇨 유발 마우스 간에서 당 신생합성 관련 유전자인 G6Pase의 발현이 유의적으로 감소하는 결과를 확인하였다(도 25 참조).As a result of confirming the expression of genes related to glycogen synthesis (G6Pase, PEPCK), it was confirmed that the expression of G6Pase, a gene related to glycogen synthesis, was significantly reduced in the liver of diabetic mice by the treatment with the Wassong·Mojicha complex extract ( see Figure 25).
이러한 실험예 8의 실험 결과를 바탕으로 와송·여주 복합추출물이 G6Pase와 같은 당 생성 효소를 조절함으로써 간에서의 포도당 신생과정을 억제하고, 인슐린 민감성을 증가시키는 것을 알 수 있다.Based on the experimental results of Experimental Example 8, it can be seen that the Wassong·Mongolia complex extract inhibits the glucose generation process in the liver and increases insulin sensitivity by regulating sugar-generating enzymes such as G6Pase.
실험예 9. 항당뇨 효능 Experimental Example 9. Antidiabetic efficacy in vitroin vitro 평가 evaluation
9-1. 실험 과정9-1. experimental process
간암세포주인 HepG2 cell에 PA(palmitic acid)를 0.4 mM 농도로 처리하여 인슐린저항성, 지방 축적 및 세포손상을 유발하였고, (1)와송 열수추출물 1 ug/mL, (2)와송·여주 복합추출물 농도 13 ng/mL, 100 ng/mL, 1 ug/mL(통계적으로 세포독성이 일어나지 않는 3가지 농도)를 처리한 후, 24시간 배양하였다.Hepatic cancer cell line HepG2 cell was treated with PA (palmitic acid) at a concentration of 0.4 mM to induce insulin resistance, fat accumulation and cell damage. After treatment with 13 ng/mL, 100 ng/mL, and 1 ug/mL (three concentrations at which cytotoxicity does not occur statistically), the cells were cultured for 24 hours.
다양한 유전자의 발현 변화를 qRT-PCR을 통하여 상대정량분석을 실시하여 와송·여주 복합추출물에 의한 유전자 발현양상의 변화를 세포수준에서 비교분석하였다.Relative quantitative analysis was performed on the expression changes of various genes through qRT-PCR, and the changes in gene expression patterns caused by the composite extracts of Wassong and Goji bitter gourd were compared at the cellular level.
9-2. 실험 결과9-2. Experiment result
(1)와송 추출물 처리 결과(도 26 참조)(1) Wasp pine extract treatment result (see Fig. 26)
지방 생성 및 대사관련 인자들의 발현이 와송 열수추출물 처리에 의하여 유의적으로 감소하는 결과를 확인하였고 PPARα의 발현은 증가시키는 결과를 확인하였다.It was confirmed that the expression of adipogenesis and metabolism-related factors was significantly decreased by the treatment with the hot water extract of Waspsong, and the expression of PPARα was increased.
와송 추출물 처리가 PA 처리 간세포에서 당 수용체 발현 증가 및 당 생성관련 인자의 발현을 감소시키는 것을 확인하였다.It was confirmed that the treatment with the Waspong extract increased the expression of glucose receptors and decreased the expression of factors related to sugar production in PA-treated hepatocytes.
이러한 결과를 바탕으로 와송 추출물이 항 당뇨 효능을 가지고 있음을 세포수준에서 확인하였다.Based on these results, it was confirmed at the cellular level that Waspsong extract has an anti-diabetic effect.
(2)와송·여주 복합추출물 처리 결과(도 27 참조)(2) Results of treatment of wasabi pine and bitter gourd complex extract (see Fig. 27)
와송·여주 복합추출물의 처리가 PA가 처리된 간세포에서 지질 축적 관련 유전자의 발현을 감소시키고, PPARα의 발현을 증가시키는 결과를 확인하였다.It was confirmed that the treatment with Wasong·Yeoju japonica extract reduced the expression of genes related to lipid accumulation and increased the expression of PPARα in PA-treated hepatocytes.
와송·여주 복합추출물의 처리가 PA가 처리된 간세포에서 GLUT4를 유의적으로 증가시키는 것을 확인하였고, G6Pase의 발현은 유의적으로 감소하는 결과를 확인하였다.It was confirmed that the treatment of Wassong·Mongolia complex extract significantly increased GLUT4 in PA-treated hepatocytes, and the expression of G6Pase significantly decreased.
이러한 결과를 바탕으로 와송·여주 복합추출물이 항 당뇨 효능을 가지고 있음을 세포수준에서 확인하였다.Based on these results, it was confirmed at the cellular level that the Wasong·Yeoju complex extract has anti-diabetic efficacy.
Claims (1)
상기 복합추출물을 마우스 경구 투여 기준으로 400mg/kg/day 포함한 식품 조성물을 제조하는 단계;를 포함하는,
당뇨병 예방 또는 개선용 식품 조성물의 제조방법.Catechin 0.7 mg/g, epigallocatechin 0.39 mg/g, epigallocatechin-gallate 0.14 mg/g, epicatechin 0.07 mg/g and epicatechin-gal To contain 0.10 mg/g of epicatechin-gallate, the above ground part of bitter gourd and bitter gourd was mixed at a weight ratio of 8:2, and 10 L of distilled water was added to 1 kg of dry powder to prepare a composite extract of bitter gourd and bitter gourd; and
Preparing a food composition containing 400 mg / kg / day of the composite extract based on oral administration of mice;
Method for producing a food composition for preventing or improving diabetes.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020220014181A KR102488212B1 (en) | 2018-09-27 | 2022-02-03 | Orostachys japonicas and Momordica charantia Linn complex-extract for improving blood sugar and method of manufacturing the same |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20180115307 | 2018-09-27 | ||
KR1020190119161A KR20200035900A (en) | 2018-09-27 | 2019-09-26 | Orostachys japonicas and Momordica charantia Linn complex-extract for improving blood sugar and method of manufacturing the same |
KR1020220014181A KR102488212B1 (en) | 2018-09-27 | 2022-02-03 | Orostachys japonicas and Momordica charantia Linn complex-extract for improving blood sugar and method of manufacturing the same |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020190119161A Division KR20200035900A (en) | 2018-09-27 | 2019-09-26 | Orostachys japonicas and Momordica charantia Linn complex-extract for improving blood sugar and method of manufacturing the same |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20220024244A KR20220024244A (en) | 2022-03-03 |
KR102488212B1 true KR102488212B1 (en) | 2023-02-06 |
Family
ID=70281862
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020190119161A KR20200035900A (en) | 2018-09-27 | 2019-09-26 | Orostachys japonicas and Momordica charantia Linn complex-extract for improving blood sugar and method of manufacturing the same |
KR1020220014181A KR102488212B1 (en) | 2018-09-27 | 2022-02-03 | Orostachys japonicas and Momordica charantia Linn complex-extract for improving blood sugar and method of manufacturing the same |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020190119161A KR20200035900A (en) | 2018-09-27 | 2019-09-26 | Orostachys japonicas and Momordica charantia Linn complex-extract for improving blood sugar and method of manufacturing the same |
Country Status (1)
Country | Link |
---|---|
KR (2) | KR20200035900A (en) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100525816B1 (en) | 2003-07-10 | 2005-11-03 | 학교법인 인제학원 | An antidiabetic composition comprising O. japonicus polysaccharide extract |
KR101770257B1 (en) * | 2015-07-31 | 2017-08-22 | 콜마비앤에이치 주식회사 | Method for preparing of bitter gourd extract enhanced biological activity and bitter gourd ethanol extract prepared by the same |
-
2019
- 2019-09-26 KR KR1020190119161A patent/KR20200035900A/en not_active IP Right Cessation
-
2022
- 2022-02-03 KR KR1020220014181A patent/KR102488212B1/en active IP Right Grant
Non-Patent Citations (2)
Title |
---|
Nutrition Research and Practice. Vol.5, No,4, pp.301-307 (2011.)* |
공개특허공보 제10-2017-0014713호(2017.02.08.)* |
Also Published As
Publication number | Publication date |
---|---|
KR20200035900A (en) | 2020-04-06 |
KR20220024244A (en) | 2022-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Gohil et al. | Treatment with extracts of Eugenia jambolana seed and Aegle marmelos leaf extracts prevents hyperglycemia and hyperlipidemia in alloxan induced diabetic rats | |
Parmar et al. | Medicinal values of fruit peels from Citrus sinensis, Punica granatum, and Musa paradisiaca with respect to alterations in tissue lipid peroxidation and serum concentration of glucose, insulin, and thyroid hormones | |
Luo et al. | Sweet potato (Ipomoea batatas L.) leaf polyphenols ameliorate hyperglycemia in type 2 diabetes mellitus mice | |
CN106573028A (en) | Composition for preventing and treating non-alcoholic fatty liver diseases | |
Lu et al. | Antidiabetic effects of total flavonoids from Litsea Coreana leve on fat-fed, streptozotocin-induced type 2 diabetic rats | |
Mehdi et al. | The effect of Persian shallot (Allium hirtifolium Boiss.) extract on blood sugar and serum levels of some hormones in diabetic rats | |
Elmosallamy et al. | Identification of polyphenolic compounds and hepatoprotective activity of artichoke (Cynara scolymus L.) edible part extracts in rats | |
Mehran et al. | Lamium album or Urtica dioica? which is more effective in decreasing serum glucose, lipid and hepatic enzymes in streptozotocin induced diabetic rats: A comparative study | |
Cyriac et al. | Anti-hyperglycemic effect of aqueous extract of Kappaphycus alvarezii (Doty) Doty ex. P. Silva in alloxan-induced diabetic rats | |
Jamrozik et al. | Hibiscus sabdariffa in diabetes prevention and treatment—does it work? An evidence-based review | |
WO2010054470A1 (en) | Pumpkin and rose hips weight loss composition | |
Wang et al. | p-Synephrine ameliorates alloxan-induced diabetes mellitus through inhibiting oxidative stress and inflammation via suppressing the NF-kappa B and MAPK pathways | |
US20100112097A1 (en) | Pharmaceutical composition for preventing and treating cancer and health food containing the same for preventing and treating cancer | |
Raafat et al. | Endogenous Lebanese plants treating diabetes and related complications | |
KR102488212B1 (en) | Orostachys japonicas and Momordica charantia Linn complex-extract for improving blood sugar and method of manufacturing the same | |
KR102438938B1 (en) | Vitalmelon (KCTC14699BP) and anti-obesity composition comprising vitalmelon extract | |
Aljazzaf et al. | Evaluation of Antidiabetic Effect of Combined Leaf and Seed Extracts of Moringa oleifera (Moringaceae) on Alloxan‐Induced Diabetes in Mice: A Biochemical and Histological Study | |
Appia Krishnan et al. | Hypoglycemic and antihyperlipidaemic effect of ethanolic extract of aerial parts of Aerva lanata Linn. in normal and alloxan induced diabetic rats | |
WO2016018799A2 (en) | Water extracts of cinnamon and radix astragali | |
KR101204415B1 (en) | Compositions for Preventing or Treating Obesity, Hyperlipidemia or Fatty Liver | |
CN111632082B (en) | American ginseng and hovenia dulcis thunb composition and application thereof in preparing medicine for preventing and treating alcoholic liver injury | |
CN110693873B (en) | Preparation and application of rabdosia rubescens active ingredient composition | |
CN110279758B (en) | Peony leaf dry powder, preparation method thereof and application of peony leaf dry powder as xanthine oxidase inhibitor | |
JP6101888B2 (en) | Fatty liver suppressant | |
KR20100111088A (en) | Composition for preventing and treating diabetes mellitus or diabetic complications comprising extract of herbal combination |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A107 | Divisional application of patent | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right |